Trinabol 150
Overview
Trinabol 150 British Dragon is a three-ester trenbolone blend delivering 150 mg/ml in a 10 ml vial — 1,500 mg total. Each millilitre contains 50 mg trenbolone acetate, 50 mg trenbolone enanthate, and 50 mg trenbolone hexahydrobenzylcarbonate. The blend is engineered on the same pharmacokinetic principle as multi-ester testosterone products: the acetate component provides fast onset (measurable blood levels within 24–48 hours of the first injection) while the enanthate and hexahydrobenzylcarbonate components sustain trenbolone levels for 7 and 14 days respectively, building toward a stable plateau over 3–4 weeks. The anabolic and conditioning profile is identical to any other trenbolone format — no aromatization, high androgen receptor affinity, strong nutrient partitioning, and prolactin liability — but the tri-ester release curve reduces the blood level lag of a hexa-only cycle while avoiding the pure EOD injection commitment of an acetate-only protocol. Trinabol 150 BD is an experienced-user compound; as with all trenbolone formats at Steroid Warehouse, it is paired with a testosterone base and active prolactin management on every cycle.
About the Compound
The three trenbolone esters in Trinabol 150 BD are pharmacologically identical once cleaved from their ester groups — all release free trenbolone, which then acts on the androgen receptor, suppresses LH/FSH, and produces the trenbolone-specific effects described throughout this page. What differs is the rate of ester hydrolysis from the injection depot. The acetate ester (propionic acid, 2-carbon chain) hydrolyses rapidly, delivering the first bolus of free trenbolone within 24–48 hours and reaching a local peak at 48–72 hours before declining. The enanthate ester (~7-day half-life) sustains trenbolone levels through the first and second weeks. The hexahydrobenzylcarbonate ester (~14-day half-life) continues releasing trenbolone through weeks 2–4, carrying the blood level plateau well past the point where acetate alone would have fully cleared.
The practical result is a blood level curve that rises fast (vs pure hexa), sustains without EOD injection burden (vs pure acetate), and reaches steady state in approximately 3–4 weeks — earlier than pure hexa (3–4 weeks) and later than pure acetate (1 week). PCT timing is governed by the longest ester: hexahydrobenzylcarbonate at ~14 days, requiring a 14–21 day post-last-injection wait before SERM therapy begins.
What It Does
- Fast onset from the acetate fraction — trenbolone active within 48 hours: unlike pure hexa or enanthate-only products, Trinabol 150 BD produces measurable trenbolone blood levels within 24–48 hours of the first injection; users do not wait 2–3 weeks for the compound to build toward effective concentrations; this is particularly valuable at the start of a 10–12 week pre-contest cycle where time matters.
- Sustained stable release from enanthate and hexa fractions: the enanthate and hexahydrobenzylcarbonate components provide overlapping sustained release; once steady state is reached at week 3–4, twice-weekly injections maintain consistently elevated trenbolone levels without the peak-to-trough oscillation of a pure acetate EOD protocol; stable levels translate to consistent AR stimulation, consistent prolactin behaviour, and predictable side-effect expression.
- Dry lean mass, conditioning, and nutrient partitioning: identical to single-ester trenbolone products; trenbolone's ~5× testosterone AR affinity drives protein synthesis and nitrogen retention without aromatization; no estrogen-driven water retention; strong nutrient partitioning effect directs dietary protein toward lean mass accretion; particularly effective at maintenance calories for recomposition, or in a deficit for pre-contest preparation.
- No aromatization — estrogen management targeted at testosterone base only: none of the three esters in Trinabol 150 BD contribute to E2; all AI dosing in a Trinabol cycle is calibrated against the co-administered testosterone; this simplifies estrogen management compared to compounds that aromatize, but it does not eliminate the need for an AI when a testosterone base is used.
- Prolactin elevation from progestogenic activity — requires cabergoline: the progestogenic activity of trenbolone is ester-independent; all three components of Trinabol 150 BD contribute to prolactin drive once cleaved; Caberlin (cabergoline) 0.25 mg twice weekly from the first injection is required, not optional.
Who It's For
Trinabol 150 BD is for experienced AAS users who have completed multiple cycles including at least one previous trenbolone cycle (acetate or enanthate) and understand their individual trenbolone response, side-effect thresholds, and AI/prolactin management requirements. The tri-ester format specifically suits users who want the fast-onset benefit of the acetate ester combined with the stable, twice-weekly injection convenience of long esters — without committing to either a pure acetate EOD schedule or a pure hexa protocol with a slow 3–4 week build.
The primary differentiator of Trinabol 150 BD from single-ester products is the pharmacokinetic curve: it behaves like trenbolone acetate in the first week (fast rise, early anabolic onset) and like trenbolone hexa from week 3 onward (stable levels, manageable injection frequency). This makes it particularly suited to 10–12 week cycles where the user needs early trenbolone activity but prefers a twice-weekly injection schedule for the duration. Compared to Trenabol Hexa BD alone, Trinabol 150 BD reaches effective levels approximately 2 weeks earlier. Compared to Trenabol 100 BD (acetate) alone, Trinabol 150 BD eliminates the EOD injection requirement after the initial weeks.
Users who should not choose Trinabol 150 BD: anyone on their first trenbolone cycle should use acetate first, where fast clearance (3–5 days) allows early discontinuation if side effects are severe; Trinabol 150 BD's hexa fraction commits the user to 2–3 weeks of declining levels after stopping. Users with a fixed PCT start date within 8–10 weeks of cycle start should note that the 14–21 day post-last-injection clearance window is governed by the hexa component regardless of the acetate fraction present. Users with a history of intolerance to trenbolone side effects (severe cardiovascular impact, unmanageable mood effects) should not use any trenbolone format.
Trinabol 150 vs Alternatives
| Compound | Key Differences | Choose Trinabol 150 BD When | Choose Alternative When |
|---|---|---|---|
| Trenabol 100 BD (trenbolone acetate 100 mg/ml) | Pure short ester vs tri-ester blend; acetate requires EOD injections vs Trinabol twice-weekly; acetate reaches stable levels in 5–7 days vs Trinabol 3–4 weeks; acetate PCT window opens 3–5 days post-last-injection vs Trinabol 14–21 days (hexa governs); at equal weekly trenbolone doses the anabolic/androgenic effect is identical; acetate allows fast cycle exit in 5–7 days if side effects are severe | Trenbolone tolerance confirmed; twice-weekly injections preferred over EOD; 10–14 week cycle where fast onset combined with stable long-ester plateau is the goal; no imminent fixed PCT deadline within 3 weeks of planned cycle end | First trenbolone cycle — use acetate for fast-exit safety; PCT start window is fixed and within 10 weeks; EOD injection compliance is not a concern; cycle is short (8 weeks) and pure acetate kinetics are more appropriate |
| Trenabol Hexa BD (trenbolone hexahydrobenzylcarbonate 100 mg/ml) | Pure long ester vs tri-ester blend; hexa takes 3–4 weeks to reach effective blood levels vs Trinabol which is active within 48 hours from the acetate fraction; injection frequency is the same (1–2×/week); PCT timing is the same (~14–21 days post-last-injection for both, as both are governed by the hexa component); anabolic/androgenic effect at equal weekly doses is identical; hexa produces a flatter, more gradual blood level curve; Trinabol produces an initial spike from acetate then a sustained plateau | Fast onset at cycle start is needed (10–12 week cycle where losing 3–4 weeks to hexa build-up is not acceptable); user wants long-ester convenience with early trenbolone activity; no bridging acetate injections desired to supplement a hexa cycle | Maximum blood level flatness preferred (pure hexa has fewer early fluctuations from the acetate component); cycle is 14+ weeks where the delayed hexa onset is not a significant fraction of total duration; hexa alone is preferred for its simpler single-ester kinetics |
| Trenbolone 200 Dragon Pharma (trenbolone enanthate 200 mg/ml) | Single long ester (enanthate ~7 days) vs tri-ester blend; higher mg/ml concentration (200 vs 150 mg/ml); enanthate reaches stable levels in ~2–3 weeks vs Trinabol's 3–4 weeks for the long-ester fraction, but Trinabol is already active in week 1 from acetate; enanthate PCT window opens at ~14 days post-last-injection; Dragon Pharma brand vs British Dragon | British Dragon brand preferred; fast initial onset needed alongside long-ester convenience; tri-ester release profile preferred | Higher concentration (200 mg/ml) preferred for lower injection volume; single-ester kinetics preferred for simplicity; Dragon Pharma brand preferred; first long-ester trenbolone run where pure enanthate kinetics are cleaner to manage |
Combinations
| Goal | Primary | Support Compounds | Notes |
|---|---|---|---|
| Cutting — classic long-ester alignment | Trinabol 150 BD 300 mg/wk 2×/week (wks 1–12) | Testabol Enanthate BD 400 mg/wk 2×/week + Anastrozole BD + Caberlin | Both compounds inject on the same twice-weekly schedule (Mon/Thu); Testabol Enanthate BD provides the mandatory testosterone base; Anastrozole BD is dosed against the testosterone component only; from week 1 the acetate fraction of Trinabol delivers early trenbolone activity; by week 3–4 the enanthate and hexa fractions plateau; Caberlin 0.25 mg twice weekly throughout; check E2 and prolactin at week 4–5; PCT starts 14–21 days after last injection of both compounds |
| Pre-contest — hardening and density stack | Trinabol 150 BD 300 mg/wk 2×/week (wks 1–12) | Testabol Enanthate BD 300 mg/wk + Mastabol 100 BD (masteron propionate) 400 mg/wk EOD + Caberlin | Trinabol 150 BD + Testabol Enanthate BD on Mon/Thu; Mastabol 100 BD (drostanolone propionate, EOD) added for conditioning and anti-estrogenic tissue effect; Mastabol BD reduces the AI requirement from the testosterone component; testosterone base kept at minimum effective dose (300 mg/wk) to reduce E2 burden; note ester mismatch between Mastabol 100 BD (short, EOD) and the long-ester compounds — Mastabol clears in 5–7 days post last EOD injection while Trinabol requires 14–21 days; stop all compounds together and wait 14–21 days for PCT |
| Recomposition — lean mass at maintenance calories | Trinabol 150 BD 300 mg/wk 2×/week (wks 1–12) | Testabol Enanthate BD 400 mg/wk + Primobol Inject BD (methenolone enanthate) 400 mg/wk + Anastrozole BD + Caberlin | Three-compound long-ester recomposition stack; all inject twice-weekly on the same schedule; Primobol Inject BD (methenolone enanthate, ~10-day half-life) contributes dry lean mass without aromatization; AI requirement is conservative with Primobolan in the mix; Trinabol 150 BD's fast-onset acetate fraction accelerates early anabolic activity beyond what a pure-hexa + Primobolan cycle would deliver in weeks 1–3; cycle length 12 weeks minimum |
| Strength peak — oral kick in final weeks | Trinabol 150 BD 300 mg/wk 2×/week (wks 1–12) | Testabol Enanthate BD 500 mg/wk + Stanabol Tablets BD 50 mg/day (wks 7–12) + Anastrozole BD + Caberlin | Trinabol 150 BD + Testabol Enanthate BD run for 12 weeks; Stanabol Tablets BD added in weeks 7–12 for final strength and hardness; stanozolol compounds trenbolone's HDL suppression significantly — mandatory lipid panel at week 8; stop all compounds simultaneously; PCT starts 14–21 days after the last injectable dose; do not extend Stanabol BD beyond 6 weeks |
Side Effects & Management
| Side Effect | Frequency | How to Handle It |
|---|---|---|
| Acetate-fraction PIP and tren cough in weeks 1–2 | Common in the first 1–2 weeks; driven by the propionate-chain acetate ester at the injection site; tren cough episodes possible with the acetate component | Warm the vial before injecting; inject slowly; aspirate before injection to avoid venule; rotate sites (glute, quad, delt); after week 2–3 the acetate fraction diminishes relative to the sustained long-ester components and PIP typically improves; tren cough episodes are transient (30 seconds to 2 minutes), self-limiting, and not a sign of an adverse event — sit or lie down and wait |
| Prolactin elevation — libido, erectile dysfunction | Common at 300+ mg/week; same mechanism as single-ester trenbolone products; the sustained stable blood levels from hexa and enanthate fractions may produce a more consistent prolactin elevation pattern than acetate-only protocols | Caberlin (cabergoline) 0.25 mg twice weekly from week 1; check prolactin at week 4–5; if elevated above reference range, increase to 0.5 mg twice weekly; continue Caberlin through the first 1–2 weeks of PCT as long-ester fractions clear; do not use an AI to address prolactin-driven symptoms |
| Night sweats and sleep disturbance | Very common; same mechanism as all trenbolone formats; stable long-ester blood levels may produce consistent night sweats throughout the cycle rather than the variable pattern sometimes seen with acetate | Cool sleeping environment; light bedding; dose reduction is the only effective strategy for severe insomnia; the acetate fraction means dose changes take partial effect within 2–3 days even on a hexa-governed plateau — but full dose reduction effects require the long esters to decline over 1–2 weeks |
| HDL suppression and lipid disruption | Consistent; severe HDL reduction across all trenbolone formats; longer 10–14 week cycles accumulate more cumulative lipid impact; significantly worsened with stanozolol co-administration | Pre-cycle lipid baseline mandatory; omega-3 4 g/day throughout; mid-cycle lipid panel at week 6–7; Atorvastatin 40 mg DP if LDL exceeds 160 mg/dL; avoid oral 17-AA AAS combinations without mandatory lipid monitoring; post-cycle lipid recovery expected within 6–12 weeks |
| Blood pressure elevation | Common; compounded by hematocrit rise and E2 from testosterone base | Weekly BP self-monitoring; target below 130/80 mmHg; manage E2 with Anastrozole BD; Ecosprin 75 mg/day throughout; if BP persists above target: Amlip (amlodipine) 5 mg/day |
| Hematocrit elevation | Common; EPO-mediated; longer cycles accumulate more RBC rise | Baseline CBC; mid-cycle at week 6–7; keep hematocrit below 52%; Ecosprin 75 mg/day when above 48%; blood donation if above 52% |
| Androgenic effects (acne, hair loss, aggression) | Common in androgen-sensitive individuals; trenbolone cannot be 5AR-reduced to a weaker metabolite in androgen-sensitive tissues; finasteride does not reduce trenbolone androgenicity | Topical skincare; Accutane (isotretinoin) for severe cystic acne; aggression and mood effects are dose-dependent; if unmanageable at entry doses (200–250 mg/week), discontinue — note that due to the long-ester fractions, full clearance takes 2–3 weeks after the last injection |
Bloodwork Monitoring
| Lab | When to Test | Target & Action Threshold |
|---|---|---|
| Prolactin | Baseline; week 4–5 (after long-ester fractions reach steady state); post-PCT (4 weeks after completion) | Male reference range; the tri-ester blend reaches stable trenbolone levels at week 3–4, making week 4–5 the first reliable mid-cycle prolactin reading; above 20 ng/mL: increase Caberlin to 0.5 mg twice weekly; continue Caberlin through PCT clearance window |
| Estradiol (E2) | Baseline; week 4 (AI calibration for testosterone base); post-cycle | Target on cycle: 20–40 pg/mL; AI is dosed against the testosterone base only; E2 responds to AI changes on the long-ester testosterone lag (~1–2 weeks); calibrate conservatively at week 4 and re-check at week 6 if adjustments were made |
| Lipid panel (HDL, LDL, TG) | Baseline (mandatory); week 6–7; post-cycle (6–8 weeks after) | HDL above 35 mg/dL on cycle; LDL below 130 mg/dL; mid-cycle lipid panel at week 6–7 allows intervention during the cycle; Atorvastatin DP if LDL exceeds 160 mg/dL |
| Hematocrit & CBC | Baseline; week 6–7 | Hematocrit below 52%; hemoglobin below 17.5 g/dL; Ecosprin 75 mg/day when above 48% |
| Blood pressure | Baseline; weekly self-monitoring | Below 130/80 mmHg; address E2 and hematocrit first; Amlip 5 mg/day if BP persists; Ecosprin 75 mg daily throughout |
| LH + FSH | Baseline; post-PCT (4 weeks after SERM completion) | Post-PCT return to pre-cycle baseline; hexa fraction governs suppression duration — SERM therapy should not begin until 14–21 days after the last injection; verify HPG recovery with bloodwork at 4 weeks post-PCT |
| Total testosterone | Baseline; post-PCT (4 weeks after completion) | Return to pre-cycle baseline; below 300 ng/dL at 6 weeks post-PCT indicates incomplete HPG recovery; document baseline before starting |
PCT
PCT timing for Trinabol 150 BD is governed by the longest ester in the blend: hexahydrobenzylcarbonate at approximately 14 days. Wait 14–21 days after the last injection before beginning SERM therapy — regardless of the acetate fraction having cleared within 3–5 days. The enanthate and hexa fractions maintain suppressive trenbolone levels for 2–3 weeks post-last-injection; starting SERM therapy while these fractions are still active reduces PCT efficacy.
If the cycle pairs Trinabol 150 BD with a long-ester testosterone (Testabol Enanthate BD, Testabol Depot BD), both the testosterone ester and the hexa fraction require approximately 14–21 days to clear. Stop all compounds on the same day; PCT starts 14–21 days later. Do not stop the testosterone base before the trenbolone blend — running trenbolone without testosterone support in the clearance window is unnecessary and counterproductive.
Standard 4-week PCT protocol:
- Weeks 1–2: Tamoxifen BD 40 mg/day + Clomiphene BD 50 mg/day
- Weeks 3–4: Tamoxifen BD 20 mg/day + Clomiphene BD 25 mg/day
HCG: For cycles of 10–14 weeks, run HCG 5,000 IU Dragon Pharma at 2,500 IU on two days within the clearance window (beginning 5–7 days post-last-injection), completing the last HCG dose at least 5 days before the first SERM dose. Continue Caberlin 0.25 mg twice weekly through the first 2 weeks of PCT as the long-ester trenbolone fractions clear. Verify HPG recovery with bloodwork at 4 weeks post-PCT.
Practical Summary
- The acetate fraction is active in week 1 — plan management compounds from day one: unlike pure hexa where side effects build gradually over 3–4 weeks, Trinabol 150 BD's acetate component produces trenbolone activity within 48 hours; start Caberlin and Anastrozole BD on the same day as the first injection — not at week 2–3 when symptoms appear.
- PCT timing is set by the hexa fraction regardless of the acetate: the acetate component of Trinabol 150 BD clears in 3–5 days, but the hexa fraction remains active for 3–4 weeks post-last-injection; do not start PCT at day 5 because the acetate is gone — wait the full 14–21 days for the hexa and enanthate to clear; this is the most common mistake on multi-ester trenbolone cycles.
- 1,500 mg per vial at 300 mg/week (2 ml) = 5-week supply: a 12-week cycle at 300 mg/week requires approximately 2.4 vials; a 14-week cycle at 300 mg/week requires 2.8 vials; round up and secure 3 vials before starting; do not begin a long-ester cycle without the full supply.
- Twice-weekly injection schedule aligns with long-ester testosterone bases: Testabol Enanthate BD (Mon/Thu, twice-weekly) pairs directly with Trinabol 150 BD on the same injection days; a single twice-weekly pin covers both compounds; this is the operational advantage of the tri-ester blend over pure acetate (EOD) for users running long-ester testosterone.
- Mid-cycle bloodwork at week 4–5 is the first reliable reading: the acetate fraction creates initial blood level variability in weeks 1–3; by week 4–5 the enanthate and hexa fractions have reached plateau and prolactin, E2, and hematocrit readings are stable and representative; calibrate all management compounds at this point rather than reacting to week 1–2 fluctuations.
- Confirmed trenbolone tolerance on a prior acetate cycle is the prerequisite: the hexa fraction in Trinabol 150 BD means any poorly-tolerated side effects persist for 2–3 weeks after stopping; never use Trinabol 150 BD as a first trenbolone cycle.
Trinabol 150 BD from steroidwarehouse.com combines the fast-onset advantage of trenbolone acetate with the stable, convenient release profile of long-acting esters in a single 150 mg/ml formulation. For experienced users who have confirmed their trenbolone tolerance and are running 10–14 week cycles paired with long-ester testosterone, it delivers the practical best of both formats: early cycle activity, twice-weekly dosing, and a conditioning profile consistent with trenbolone's established role in pre-contest and recomposition protocols. The tri-ester design does not change trenbolone's fundamental monitoring requirements — testosterone base, cabergoline from day one, mandatory prolactin and lipid bloodwork, and a structured PCT starting 14–21 days after the last injection remain the non-negotiable framework for every Trinabol cycle.
References
| Source | Topic | Link |
|---|---|---|
| New England Journal of Medicine / PubMed | Bhasin S et al. 1996 — randomized controlled trial evaluating 600 mg/week testosterone enanthate in healthy men with and without resistance training; demonstrated significant increases in fat-free mass, muscle size, and strength, especially when supraphysiologic testosterone was combined with resistance training | Bhasin S, et al. (1996) ↗ |
| Sports Medicine / PubMed | Hartgens F & Kuipers H 2004 — review of androgenic-anabolic steroid effects in athletes; covers strength and bodyweight changes, body composition, erythropoiesis, lipid profiles, cardiovascular effects, endocrine suppression, hepatic effects, and psychological considerations across anabolic-androgenic steroid use in sport | Hartgens F & Kuipers H (2004) ↗ |
| NCBI Bookshelf / StatPearls | Anabolic steroids overview — clinical reference on anabolic-androgenic steroids including testosterone derivatives and injectable esterified AAS; covers androgen receptor mechanism, HPG-axis suppression, adverse effects, misuse patterns, and monitoring considerations | StatPearls: Anabolic Steroids ↗ |
| NCBI Bookshelf / Endotext | Androgen physiology and pharmacology — comprehensive overview of testosterone biosynthesis, androgen receptor signaling, HPG-axis regulation, aromatization, synthetic androgen pharmacology, and endocrine suppression from exogenous androgen use | Endotext: Androgen Physiology, Pharmacology, Use and Misuse ↗ |
| The Lancet / PubMed | Basaria S 2014 — clinical review of male hypogonadism; covers testosterone physiology, causes of androgen deficiency, diagnostic evaluation, testosterone therapy, treatment monitoring, and safety considerations relevant to suppressed endogenous testosterone states | Basaria S (2014) ↗ |
What is Trinabol 150?
Trinabol 150 is an injectable anabolic steroid blend (Trenbolone Acetate, Hexahydrobenzylcarbonate, Enanthate) for muscle growth and fat loss; see What is Trinabol 150. It's potent—consult professionals for safe use.
What does Trinabol 150 do?
It promotes muscle growth, strength, and fat loss; see What Does Trinabol 150 Do. It enhances physique—monitor with labs.
How do I take Trinabol 150?
150-300 mg/week, injected every other day or twice weekly; see How to Take Trinabol 150. Start low—consult professionals for dosing.
How to cycle Trinabol 150?
8-10 weeks, 150-300 mg/week, PCT after 10-14 days; see How to Cycle Trinabol 150. Stack with testosterone—consult professionals.
How does Trinabol 150 work?
Trinabol 150 works by combining multiple trenbolone esters that release at different rates, helping maintain active hormone levels while supporting protein synthesis, nitrogen retention, and muscle development.
How long does it take to notice effects from Trinabol 150?
Because it contains both short-acting and long-acting esters, users often report early performance-related effects while longer-term physique and strength improvements continue to develop over several weeks.
What are the main benefits of Trinabol 150?
Commonly reported benefits include increased lean muscle mass, enhanced strength, improved muscle hardness, accelerated recovery, improved body recomposition, and a dry, defined physique appearance.
What are the possible side effects of Trinabol 150?
Potential side effects may include increased sweating, insomnia, mood changes, acne, elevated blood pressure, and suppression of natural testosterone production.
Related Products
- Promotes rapid muscle growth and strength gains.
- Enhances fat loss for a lean, defined physique.
- Improves muscle hardness and vascularity.
- Delivers quick anabolic effects with minimal water retention.
- Promotes rapid muscle growth and strength gains.
- Enhances fat loss and lean muscle retention.
- Boosts nitrogen retention for anabolic effects.
- Improves vascularity and hardness.
